email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2638-5910

Archives of Diabetes & Obesity

Review Article(ISSN: 2638-5910)

Diabetes Mellitus: Classification, Genetic Association and Herbal Treatment Volume 2 - Issue 2

Zainab Feroz1, Sivakumar Vijayaraghavalu2, Noohu Abdulla Khan3, Narasimman Gurusamy4, Girish C Shukla5 and Munish Kumar1*

  • 1Department of Biochemistry, University of Allahabad, India
  • 2Central Research Facility, Sri Ramachandra Institute of Higher Education and Research, India
  • 3Department of Clinical Pharmacy, King Khalid University, Saudi Arabia
  • 4Department of Pharmacology, King Khalid University, Saudi Arabia
  • 5Department of Biological Sciences, Cleveland State University, USA

Received:July 29, 2019   Published: August 06, 2019

Corresponding author:Munish Kumar, Department of Biochemistry, University of Allahabad, India

DOI: 10.32474/ADO.2019.02.000136


Abstract PDF


Diabetes Mellitus (DM; chronic metabolic disorder) is turning out to be pandemic with India (2nd most populous country) as its epicenter; preying on health and economy of people of all ages, sex, and ethnicity. It affects all the major systems of the human body and is an underlying factor for all the other ailments, including cancers. Available anti-diabetic drugs are only able to reduce the detrimental effects of diabetes and its related complications, but still, the complete cure is unabated. Additionally, in low-middle-income countries, the economic burden of drugs on the common man is a major hindering issue in the management of disease outcome. Among the general population, the most commonly known types of this disease are type I and type II DM. Despite strenuous efforts taken by governments throughout the world, including India; due to asymptomatic nature and lack of awareness, there is still lag in understanding and management of other less commonly known DM’s. This review highlights the detailed classification of DM’s and the underlying genetic factors. As well as enlist few cost-effective herbal therapies to combat the disease.

Keywords:Diabetes Mellitus; Gestational Diabetes; Classification; Diabetic Ketoacidosis; Genes; Herbal Therapy; Diabetic complications

Abbreviations:DM: Diabetes Mellitus; GDM: Gestational Diabetes Mellitus; DKA: Diabetic Ketoacidosis; MODY: Maturity Onset Diabetes of the Young; FCPD: Fibrocalculous Pancreatic Diabetes; MIDD: Maternally Inherited Diabetes with Deafness; RAAS: Renin Angiotensin Aldosterone System; eNOS: Endothelial Nitric Oxide Synthase


Diabetes mellitus (DM), a disease of the endocrine pancreas in which either pancreatic islets secrete insufficient insulin, or there is inefficient utilization of insulin; thus, producing hyperglycemic effects and other metabolic complications. According to the global estimates of American Diabetes Association; 500 million (age range 18-99 years) were diabetics in 2018 and the number could escalate to 693 million by 2045 (International diabetes federation; 2017). Further, half of the total diabetics were asymptomatic and undiagnosed [1]. Hence, DM and its associated complications are becoming one of the major causes of mortality [2]. The serious detrimental stride of diabetes is that it could enhance the risk of developing cancers in various organs such as liver-, breast-, bladder-, kidney- and bladder [3]. The risk factors contributing to diabetes include- genetics, environment, lifestyle, and certain drugs [4]. Unlike in the past centuries; the disease is currently becoming pandemic - affecting all ages and sex and its management including economic and social burden is of concern for policy makers of high-, middle- and low-income countries [3].

DM Classifications

In addition to well-known type –I and – II DM; pregnancyassociated gestational DM (GDM) is the third most common DM. Other types include Monogenic DM (MODY), Fibrocalculous Pancreatic DM (FCPD) and Maternally Inherited Diabetes with Deafness (MIDD). Another variant of this complex disease includes genetic syndrome, certain drugs and diseased conditions, infections and hormonal- induced DM [5,6]. Brief descriptions about different types of DMs’ are as follows.

Type I DM: Type-I or insulin-dependent DM; is an autoimmune condition in which the pancreatic islets are destroyed by the cytotoxic and delayed hypersensitive T lymphocytes. The disease susceptibility increases in HLA – D type inherits, especially in children and young adults; hence classified as Juvenile - onset diabetes; it accounts for 5-10% of all people with diabetes. As proposed by the WHO and American Diabetics Association, type I diabetes can be classified as type IA and type IB. Type IA is immunemediated diabetes destroying pancreatic β cell and absolute insulin deficiency. Type IB is idiopathic diabetes in which the diabetics lack the immunological marker for autoimmune destruction of the pancreatic β cell. This form of DM also results in insulin deficiency and a tendency to develop ketosis, thereby requiring exogenous insulin as a therapeutic agent [3].

Diabetic Ketoacidosis (DKA): DKA is an acute life-threatening complication characterized by hyperglycemia (>250 mg/dl), metabolic acidosis (pH ˂ 7.3) and serum bicarbonate (˂ 15 mEq/ dl) with a significantly raised anion gap and presence of ketone bodies in the blood and/or urine [7]. Inadequacy of insulin dosing/ schedule, non-compliance or infrequent insulin injection and infection are major factors for its inception [7]. In 44% of DKA cases, non-compliance is the causative factor for its onset. Ailments of cardiovascular systems including myocardial infarction, stroke, and acute thrombosis; gastrointestinal tract disorders such as bleeding and pancreatitis; endocrine-related diseases such as acromegaly, Cushing`s syndrome and hyperthyroidism are some other contributors for the onset of DKA. In certain instances, even recent surgical procedures leads to the development of DKA caused mainly due to dehydration, increased insulin counter regulatory hormones, and worsening of peripheral insulin resistance [8]. Additionally, even a class of type II management drug - sodiumglucose cotransporter -2 (SGLT-2) inhibitors were reported to induce DKA; other classes of drugs such as, beta-blockers, corticosteroids, second-generation anti-psychotics, anti-convulsants and immune checkpoint inhibitors adds to the list. Non-drug-induced DKA includes psychological problems, binge eating and insulin pump malfunction.

Pathophysiology of DKA: In DKA, complete lack of insulin leads to impaired glucose utilization, which in-turn results in gluconeogenesis, glycogenolysis and decreased peripheral glucose uptake and thereby leading to hyperglycemia. In addition, impaired glucose utilization also leads to an increase in lipolysis, decreased lipogenesis and overproduction and urinary loss of ketone bodies [7]. In addition, glycogen and protein is catabolised as an alternative energy source to form glucose. Combination of these factors contributes to the formation of hyperglycemic condition, leading to osmotic diuresis which ultimately results in dehydration, metabolic acidosis and hyperosmolar state and subsequent decrease in glomerular filtration [8]. Potassium utilization by the skeletal muscles is highly depleted due to impaired insulin action and hyperosmolar state, resulting in intracellular potassium depletion [8].

Type II DM

Type II DM is the most common and accounts for 90-95% of all diabetes types [3]. This type of diabetes also called as non-insulin dependent DM and there is no exogenous dependence on insulin by the type II diabetics, but it may be required in case of uncontrolled blood glucose levels [3]. Interaction between genetics, environment and behavioral risk factors leads to the progression of type II DM [9].

Pathophysiology: Type II DM is characterized by hyperglycemia, insulin -deficiency and -resistance and eventually β-cell failure [9]. Insulin resistance is a condition in which there is impaired insulin action in proportion to its blood concentration. Sufficient amount of insulin is secreted by the pancreatic islets, but the tissues are relatively insensitive to insulin action and show inadequate response towards it. β-cells maintain normal glucose tolerance by increasing the insulin output. When β-cells are not able to release sufficient insulin for glucose uptake leads to elevation in glucose concentration. The threshold at which glucose stimulate insulin secretion is determined by glucokinase, which also mediates the conversion of glucose to glucose- 6-phosphates. In insulin resistance, pancreatic β-cell is marked with increased hexokinase activity, rendering the secretion of insulin at lower glucose concentration. It has been suggested that β-cell failure could be induced by apoptosis on long-term exposure of pancreatic islets to free fatty acids which inhibits glucose-induced insulin secretion and biosynthesis [3].

Insulin Action: Insulin-induced effects are seen through modulation of cytosolic enzymes and the control of gene expression. The general action of insulin is to promote anabolic process in a cell, while causing a reduction in catabolic process. Insulin is detected on the plasma membrane of the target cell by insulin receptor (INSR), which is a tetrameric glycoprotein contains insulin-binding two α subunits, and tyrosine kinase-binding two β subunits [10]. Insulin binding to INSR leads to its activation and involve signaling events which can be functionally divided into mitogenic and metabolic signals [10].

a) Mitogenic Signals

Mitogenic signals involve activation of mitogen-activated protein kinase (MAPK) pathway, which is activated when IRS interacts with adaptor protein Grb2 through its SH2 domain. Grb2 also binds to Son of Sevenless (SOS), which is a guanine nucleotide exchange factor (GEF) and catalyses the exchange of GDP for GTP on Ras, which in turn activates Raf kinase and lead to the phosphorylation and activation of MAP kinase cascade [11]. One of the end results of the activation of this cascade is the alteration of gene expression. MAPK pathway may regulate DNA binding, protein stability, cellular localization, transcription, repression, and nucleosome structure by targeting components at gene promoters. These pathways alter gene expression through phosphorylation and regulation of transcription factors, co-regulatory proteins and chromatin proteins [12].

b) Metabolic Response

Metabolic activities of insulin primarily involves catabolic (action of glycogen phosphorylase), anabolic (action of glycogen synthase) and PI3K pathway mediated GLUT4 translocation. Activated INSR phosphorylates protein phosphatase 1 (PP1), which dephosphorylate glycogen synthase (activating it) and glycogen phosphatase (inactivating it), leading to increased glycogen synthesis and inhibition of glycogenolysis. Activated INSR also leads to the activation of PKB. Glycogen synthase kinase 3β (GSK3β) is one of the substrates of PKB, which becomes inactivated upon phosphorylation and leading to inhibition of glycogen synthase activity [11]. Multi-phosphorylation of insulin receptor substrate (IRS), essentially IRS1 and IRS2 marks the key event in the signal transduction. On phosphorylation, IRS1 creates binding sites for the SH2 domain of other proteins such as PI3K. Activated PI3K leads to the production of PIP2 and PIP3, which in turn activate phospho-inositide dependent kinase 1 (PDK1). PDK1 is capable of phosphorylation and activation of PKB and PKC. Signaling events from PKB and PKC will lead to the translocation of GLUT-4 transporter to the plasma membrane (Figure 1).

Figure 1: Insulin signaling events.


Gestational Diabetes Mellitus (GDM)

GDM is a well- known variant of DM that develops during pregnancy and ceases at its end [11]. GDM can be defined as any degree of glucose intolerance which is detected for the first time during the gestational period. Women with marked obesity, glycosuria, personal history of GDM or family history of diabetes are at high risk of developing GDM. The diagnosis criteria for GDM include a fasting plasma glucose >126 mg/dl (6.9mmol/l) plus a 2-h value of 140-199 mg/dl (2.9- 11.1 mmol/l) or casual plasma glucose > 200mg/dl [13]. Due to high levels of placental hormone and with an increase in maternal adiposity, there is a progressive increase in insulin resistance and a decrease in insulin sensitivity. These changes are accompanied by changes in the glucose levels which reverse upon delivery in normal condition. Women who are not able to respond appropriately to these pregnancies related changes become hyperglycemic and develop a condition called GDM [14]. Pregnancy-related complications like diabetic fetopathy, fetal macrosomia, still births, neonatal metabolic disturbance, etc. are associated with gestational diabetes. Problems exhibited by hyperinsulinemic infants include hypocalcemia, hyperbilirubinemia and plethora. Women who had developed GDM are at seven fold higher risk of developing diabetes in later years [5]. The risk of getting diabetes and obesity increases in children born with gestational diabetic mothers [13].

Other Specific Types of Diabetes

Maturity-Onset Diabetes of the Young (MODY): MODY is a heterogeneous form of DM that is caused by a single gene defect. MODY is non-ketonic diabetes characterized with an autosomal dominant mode of inheritance, partly preserved pancreatic β-cell function and an early onset usually before 25 years of age [3, 15, 16]. MODY 1-14 types have been reported [17]. MODI 1 is caused by a mutation in HNF4A gene while a mutation in GCK gene is responsible for MODY 2 and is characterized by the occurrence of phenotypes immediately after birth and a mild increase in fasting glucose level [18]. The gene for MODY3 is HNF1A [19] and its clinical features includes hyperinsulinemic hypoglycemia in the neonatal period and macrosomia [18]. The onset age of MODY 3 is dependent upon the paternal or maternal inheritance of mutation and also on the maternal affected status when a mutation is of maternal inheritance [15]. Mutation in exon 4 of HNF1A results in the generation of pancreatic autoantibodies and diabetic ketoacidosis [19]. However, MODY 4 has not yet been reported in India and Japan [5,15]. MODY 5 is caused by the defects in transcription factor - hepatocyte nuclear factor 1 homeobox B (HNF1B). In MODY 5 insulin secretion is decreased since the early stage but is often diagnosed during adulthood. This form is characterized by frequent mutations of monoallelic defects in all or some exons and by multiple phenotypes most commonly being renal diseases. MODY 6 is caused by the mutation in the transcription factor NEUROIDI, which is known to be involved in gene activation of sulfonylurea factor 1 and expression of GCK gene thus contributing to different roles from synthesis to secretion. Homozygous mutation in NEUROIDI gene leads to neurological abnormalities and permanent neonatal DM [20].

Fibrocalculous Pancreatic Diabetes (FCPD): FCPD is an unusual diabetes phenotype restricted exclusively to the developing countries residing in the tropical regions of the world with the highest prevalence in southern India [21,22]. FCPD is predominantly described in lean young adults of either sex with a long- standing history of abdominal pain and steatorrhea. FCPD is non-alcoholic chronic pancreatitis that results from a specific type of pre-existing diabetes termed as Tropical Calcific Pancreatitis (TCP) [23]. Severe insulin dependent but ketosis resistant diabetes occurs in FCPD and patients with this phenotype develop microvascular complications and are more prone to develop dreaded complications like pancreatic malignancy [21, 24]. Although the exact etiology of FCPD has not yet been elucidated, it has been proposed to be associated with malnutrition, cassava consumption (cyanogens toxicity), toxins, micronutrient deficiency, oxidative stress, anti-oxidant depletion, free radical injury, beta cell autoimmunity and genetic factors [22,25]. HLA-DQ9 allele, HLADQB1 allele, loss of function mutation in chymotrypsinogen C gene and cathepsin B gene, SPINK1 gene (serine protease inhibitor), and CFTR gene are some of the genetic factors involved in the pathogenesis of FCPD [22].

Maternally Inherited Diabetes with Deafness (MIDD): MIDD, caused by mitochondrial gene mutations, is a rare form of diabetes characterized by pancreatic disorder and hearing impairment [26]. It has been reported that MIDD not only affect two organs i.e. pancreas and ears leading to diabetes, hypoacusis and anacusis; but has been found to manifest its effects on multiple organs and hence termed as mitochondrial multi-organ disorder syndrome (MIMODS) [27]. MIDD could confer its effect on the central nervous system (CNS), endocrine organs, peripheral nerves, ears, eyes, kidneys, heart, vestibular system and gastrointestinal tract [27]. Subjects affected with MIDD are under high prevalence of developing microvascular and macrovascular complications and rapid progression to insulin therapy [28].

Secondary Causes of Diabetes: Exogenous factors and some specific disease condition could also secondarily develop diabetes. For example, intake of some medications like corticosteroids, calcineurin inhibitors, thiazide diuretics, antipsychotics, HIV protease inhibitors, γ-interferon and statins may lead to the development of diabetes [26]. Drugs like nicotinic acid and glucocorticoids can affect to impair glucose action. Viral infections like hepatitis C infection, rubella, mumps, coxasckievirus, cytomegalovirus and adenovirus have been associated with β- cell destruction [29]. Hormonal excess, including growth hormone, cortisol, glucagon, epinephrine are some other secondary causes of diabetes. Genetic syndrome like Down syndrome, klinefelter syndrome, Turner syndrome, Wolfram syndrome, Huntington chorea, porphyria, etc. are accompanied by an increased incidence of diabetes. Specific disease conditions like stiff-man syndrome, systemic lupus erythematosus and other autoimmune diseases have anti-insulin receptor antibodies that block insulin binding to its receptor [26] Figure 2.

Figure 2: DM-Classification.


Genes Associated with DM

Type I DM

Type I diabetes is a multifactorial disease with a strong genetic association. Family history association for the disease is missing in about 85% cases with TI DM; however, evidence suggests that the risk of developing TI DM is 15 times greater in siblings of the diseased than in the normal subjects [30]. Moreover, the concordance rates for TI DM in monozygous twins are high upto 33% to 40% [31].

HLA Alleles: HLA class II allele present on chromosome 6p21 with loci HLA-DRB1 and HLA-DQB, accounts for up to 30% -50% of genetic risk for TI DM. The haplotypes DR3-DQA1*0501- DQB1*0201 (DR3) and DR4-DQA1*0301- DQB1*0302 (DR4) are at the greatest risk for T1D (32). HLA-A, - B & -C alleles have also been known to be associated with T1D independent of DR/DQ [33,34].

Non- MHC Genetic Factors: Multiple non-MHC loci including insulin, PTPN22, CTLA4, IL2RA, IFIH1, etc have been confirmed as susceptible gene markers for TI DM. It has been reported that after HLA alleles, the genetic contribution of INS gene and PTPN22 genes have been the most with reference to the diabetes risk, however, even the strongest non-MHC loci have smaller effects [33].

Type II DM

There is a strong inheritable genetic correlation in type II diabetes. Studies have found that there is 40% lifetime risk of developing TII DM for the offspring who have one of the affected parents and the risk increases upto 70% for the offspring with both the affected parents [35]. Moreover, the concordance rate of about 70% has been observed in monozygotic twins and about 20%- 30% in dizygotic twins [36]. Multiple genes involved in insulin signaling, insulin secretion, insulin resistance, glucose metabolism, obesity, diabetes co-morbidity and hormone processing protease genes have been known to be associated with TII DM [37]. Unlike TI DM, multiple gene interactions results in the progression of TII DM. A number of TII DM risk genes have been identified using candidate gene studies, linkage-based studies and genome-wide association studies (GWAS) including transcription factor 7-like 2 (TCF7L2), calpain 10 (CAPN10), peroxisome proliferator-activated receptor gamma (PPARG), insulin receptor substrate 1(IRS1), IRS2, potassium inwardly–rectifying channel, subfamily J (KCNJ11), Wolfram syndrome 1 (WFS1), HNF1 homeobox A (HNF1A), HNF1B, HNF4, hematopoietically expressed homeobox (HHEX), insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2), FTO, NOTCH2, JAZF1, SLC30A8 and others [9,29]. More than 40 genetic loci have been known to be linked to TII DM. Some of the recently discovered genes that may have a profound impact on the progression and pathogenesis of TII DM are mentioned below.

Renin Angiotensin Aldosterone System (RAAS): The RAAS is considered as an endocrine system which consists of several RAAS genes including renin, angiotensinogen (AGT), angiotensin converting enzyme (ACE), ACE2, angiotensin II type 1 receptor (AT1R) and AT2R. The RAAS genes have been known to play a profound role in glucose metabolism and blood pressure regulation [38]. Gene polymorphism of RAAS may be responsible for the development of diabetes and its associated complications. The levels of angiotensin II (AngII), the main vascular peptide are elevated due to the activation of RAAS; resulting in glucose homeostasis and progression of DM through inhibition of signal transduction, reduction of glucose uptake, insulin resistance and pancreatic β-cell destruction by oxidative stress induction [39]. Angiotensinconverting enzyme (ACE) is responsible for the metabolism of a vasodilator bradykinin and conversion of angiotensin I to active angiotensin II. I/D polymorphism of Angiotensin-Converting Enzyme (ACE) have been studied for its association with diabetic nephropathy in diabetic patients [38].

Glucose Transporter (Glut) Family: GLUT proteins are the members of the major facilitator superfamily of membrane transporters. GLUT proteins are encoded by SLC2 genes and have been proposed as candidate genes for TII DM [40]. This is a family of structurally related proteins that facilitate the transport of monosaccharides, polyols and small carbon compounds across the cell membrane of eukaryotic cells [41]. About fourteen GLUT isoforms have been isolated and classified into three classes based on sequence similarity. Class 1 (GLUTs 1-4, 14); Class 2 (GLUTs 5, 7, 9 and 11); and Class 3 (GLUTs 6, 8, 10, 12 and HMIT) (41). GLUT 2, encoded by SLC2, is mainly expressed by the hepatocytes, intestinal absorptive cells, by proximal convoluted tubular cells of the kidney, pancreatic β-cells and neurons present in the brain and erythrocytes; while GLUT4, encoded by SLC4, is mainly restricted to tissues with insulin-stimulated glucose uptakes such as adipose tissue, skeletal muscle and cardiac muscles [40]. Variations in mRNA expression of these GLUTs are associated with the pathogenesis of TII DM.

Vitamin D: Studies have shown that vitamin D deficiency is associated with a decrease in insulin release, insulin resistance and TII DM [42]. It has also been shown that the risk of developing diabetes in adulthood decreases when vitamin D supplementations are taken during the early years of life [43]. Activation of vitamin D occurs when it is bound with its specific nuclear vitamin D Receptor (VDR) [44].When intracellular VDR is bound with the activated form of vitamin D; 1, 25(OH)зDз, it can enhance pancreatic β-cell function, protect β-cell from immune attack, enhance immune receptor sensitivity and reduce immune resistance [45]. Location of VDR gene is on chromosome 12q12-q14 and its genetic alterations could lead to defects in gene activation or changes in the VDR protein structure, affecting the cellular functions of vitamin D [45]. Glucose intolerance may develop due to high parathyroid hormone concentration which is enhanced when the deficiency of vitamin D causes secondary hyperparathyroidism. Insulin resistance could also develop through the increased inflammatory condition which is associated with vitamin D deficiency [42]. The anti-inflammatory effects of vitamin D improve islets cell function, aids in insulin release and decrease insulin resistance [46].

Endothelial Nitric Oxide Synthesis (eNOS): Diabetic nephropathy is the common causal factor for Chronic Kidney Disease (CKD), stroke and heart attack. It has been estimated that about 30% of the diabetic patients develop diabetic nephropathy [47]. Although many cell types are involved, evidence suggests that endothelial dysfunction serves as a major event in the development and progression of diabetic vascular complications, including nephropathy [48]. Multiple endothelial functions involve a critical role of Nitric Oxide (NO) produced by endothelial cells through eNOS. Endothelial dysfunction in diabetes could greatly arise as a result of a decrease in NO production and bioavailability [49]. Moreover, the results have also suggested that the combined effects of eNOS deficiency and hyperglycemia contribute to podocytes injury in diabetes [50] Table 1.

Table 1: Susceptibility loci associated with Type II DM. Showing the susceptible genes, gene region, single nucleotide polymorphisms (SNPs) of particular genes and their related function in correlation to Type II DM.


Table 1 Abbreviations: KCNJ11- potassium voltage gated channel subfamily J member 11, PPARG- Peroxisome proliferator activated receptor gamma, ABCC8- ATP Binding cassette subfamily C member 8, IRS1- insulin receptor substrate 1, TCF7L2- transcription factor 7 like 2, CAPN10- Calpain 10, KCNNQ11- potassium voltage gated channel KQT like subfamily member 1, IGF2BP2- Insulin like growth factor 2 MRNA binding protein 2, HHEX- hematopoietically expressed homeobox protein, JAZF1- juxtaposed with another zinc finger protein 1, ATR- Angitensin II type 1 receptor, AT2R- Angitensin II type 2 receptor, CDKN2A/B- Cyclin dependant kinase inhibitor-2A/B, MTNR1B- Melatonin receptor 1B, VDR- vitamin D receptor.


Based on the studies related to the candidate gene approach and genome-wide association study, it has been suggested that GDM share similar genetic background with TII DM since insulin resistance and defect in insulin secretion contribute in the etiology of both TII DM and GDM [17] such as CDK5 regulatory subunit associated protein 1 like-1 (CDKAL1), transcription factor 7-like2 (TCF7L2), hexokinase domain containing 1 (HKDC1), HNF4A has been associated with both TII DM and GDM (17, 52). Candidate gene approach has also shown that GDM also shares a similar genetic background with TI DM. HLA DR3 and DR4 antigens have been associated with GDM and have been found to be higher in women with GDM. Moreover, GCK variations significantly contribute to the risk of both GDM and MODY2 [52].


Genetic studies demonstrated that development of MODY may have many causes in addition to a single genetic entity. Mutations in HNF1A (MODY3) and GCK (MODY2) are the common causes of MODY and accounts for 30-60% of all MODY while mutations in HNF4A (MODY1), HNF1B (MODY5) and INS (MODY10) are its less commonly causes, accounting for about 10% of all MODY [53,54]. Other mutations including ABCC8 (MODY12), APPL1 (MODY14), BLK (MODY11), CEL (MODY8), KCNJ11 (MODY13), KLF11 (MODY7), NEURODY (MODY6), PAX4 (MODY9) and PDX1 (MODY4) accounts for less that 1% of all MODY [54].


Recently reports have suggested increasing evidence of clustering of FCPD in families, indicating a possible genetic association of the disease [55]. DQ1, HLA-DQ9 and HLA-DQB1 allele are the potential candidate for FCPD. Studies have reported that in India, TAQ1 restriction fragment length polymorphism of DQ1 gene and have been associated with FCPD [22]. HLA-DQB 1 allele RFLP has been associated with FCPD pain in southern India and Bangladesh, similar to TI DM [22,56]. Major Histocompatibility Complex (MHC) has also been found to be associated with Bangladeshi subjects [56]. The hypervariable region of insulin gene (INS) has been associated with some FCPD patients possessing class 3 allele; similar to TII DM found in some ethnic group [57]. Thus, it can be said that FCPD shares the genetic susceptibility features similar and dissimilar to both TI DM and TII DM.


Patients with MIDD show a strong family history of diabetes, deafness and retinal dystrophy, indicating that MIDD has a strong genetic association. Studies have shown that mutation in Mitochondrial DNA (mt-DNA) contribute to the development of MIDD since mitochondrial oxidative phosphorylation (OXPHOS) plays a crucial role in glucose-stimulated insulin secretion from pancreatic β-cell [58]. Mutations in mt DNA 3243A>G in tRNA is the cause of MIDD in upto 85% of the cases reported but other mt DNA mutations could also be the causal factor [27]. Premature aging of β-cells and reduction in insulin secretion is the prominent cause of diabetes development through this mutation [59] Table 2.

Table 2: Susceptibility loci of various diabetes types. Showing the genetic factors associated with Type I DM, Type II DM, Gestational DM, MODY, FCPD and MIDD.


Table 2 Abbreviations: HLA- Human leukocyte antigen, PTPN22- Protein tyrosine phosphate, non receptor 22, CTLA4- cytotoxic T lymphocyte associated protein 4, IL2RA- interleukin receptor 2 subunit alpha, WFS- Wolfram like syndrome, HNF- Hepato nuclear factor, AGT-Angiotensinogen, ACE- Angiotensin converting enzyme, SLC- Solute carriers, HKDC- Hexokinase domain containing 1, GCK- Glucokinase, INS- Insulin, APPL1- Adaptor protein phosphotyrosine interacting with PH domain and leucine zipper, BLK- B lymphocyte kinase, CEL- Carboxyl ester lipase, PAX- Paired box, MHC- Major histocompatibility complex.

A Need for Herbal Treatment?

Insulin therapy and synthetic anti-diabetic drugs such as thiazolidinediones and sulfonylureas are commonly used to reduce the glucose level in diabetic patients; however, their major limitation is that they often fail to maintain a normal glucose concentration range and desirable glucose homeostasis within the body [60]. These drugs often tend to develop resistance and loose effectiveness after a few years of their use. Continued use of insulin treatment could enhance the risk of hypoglycemia and arteriogenesis. A drug such as thiazolidinediones might develop liver toxicity; vigorous use of sulphonylureas may become the cause of hypoglycemia, weight gain and heart disorder; use of glucoside inhibitors over an extended period may be accompanied with bloating, flatulence, diarrhea and abdominal pain [61]. The increased incidence of diabetes, the inefficiency of synthetic medicines, their sky-reaching costs and their detrimental side effects have propagated an urgent need for the development of natural, indigenous, pocket- and health- friendly herbal products for the treatment and complete cure of diabetes.

Treatment of Diabetes with Herbal Plant Products

In addition to maintaining a normal glucose level and homeostasis, herbal products have also been proven for their ability to reduce and prevention of secondary complications which are accompanied with diabetes. Some plant based products are effective in overcoming resistance and in the regeneration of pancreatic β-cells. Although several medications and drugs are available to reduce the detrimental effects of diabetes and its complications, the limitations of these therapies are its high cost and serious side-effects [62]. Medicinal plants are being looked-up for their easy availability, lesser side-effects and cost-effective treatment. The hyperglycemic condition developed due to diabetes enhances the formation of free radicals which induce the modification of extracellular proteins such as elastin, laminin and collagen to form a glycoprotein. Diabetes-associated complications including cataract, microangiopathy, atherosclerosis and nephropathy develop when these extracellular proteins of lens, vascular walls and basement membrane are modified [63]. The pathophysiology of diabetes and related complications include the involvement of free radicalinduced damage and oxidative stress which suggests that medicinal plant with antidiabetic anti-inflammatory and antioxidant property could be the suitable treatment method to neutralize the effects of free radicals [63]. Many herbal drugs indigenous to different Asian countries were claimed as anti-diabetic by traditional medical practitioners. Despite the medicinal herbs, some of the plant based foods that are commonly consumed world-wide on a day-day basis such as tulsi, garlic, aloe vera, bitter melon, pumpkin, lotus root, wheat, tomato, celery, Jerusalem artichoke, soy bean, asparagus, beet root, blackberry, Indian mustard and yoghurt were also proved to possess anti-diabetic activity by scientific studies across the globe [63,72, 96,99,100,101,102].

In line with this an interesting randomized, double-blinded, placebo controlled clinical study shown the combinatorial effect of Jerusalem artichoke and fermented soybean powder mixture as anti-diabetic (64). An article published earlier reviewed the anti-diabetic nature of the Chinese herbs approved by the Chinese health regulatory agency for commercial use in China [65]. Among the approved plants those that are rich in polysaccharide (seven herbs) were able to restore the functions of pancreas and also increased the insulin output by functional beta cells (seven herbs). Further, herbs such as Pueraria lobata and Hirudo nipponia were reported to improve the microcirculation and thereby increase the availability of insulin and regulate the metabolism. Puerain an active component of Pueraria lobata was reported to treat cardiovascular complications and shown significant hypoglycemic activity in alloxan induced diabetic mice [65]. The major advantage of natural anti – diabetic agent over the synthetic drugs as antidiabetics is its lesser side effects. It also acts in synergy with conventional drugs and enhance its efficacy, thereby dosereduction, - frequency and -scheduling can be achieved without compromising the therapeutic outcome of the conventional drugs. Many Chinese herbs either as monotherapy or in combination were shown to reduce cholesterol and triglycerides levels; hence their long – term use may be advantageous to combat the diabetes and its associated complications than conventional drug(s). In addition to these Chinese herbs some of the Indian spices and herbs were also reported to possess anti-diabetic activity. For example, 4-hydroxyleucine, an amino acid present in seeds of Trigonella foenum graecum (fenugreek), one of the major spices of India, was reported to enhance the glucose-stimulated insulin release by islet cells in both pre-clinical and clinical trials. A dose-dependent reduction in the blood glucose level in both normal and diabetic rats has been found on oral administration of 2-8 g/kg of fenugreek plant extract [63,66].

Cinamomi cassiae (cinnamon bark) is one of the traditional herbs for the treatment of diabetes and other ailments in many countries over the world due to its anti-diabetic, anti-inflammatory, antibacterial and antioxidant properties. The major components of cinnamon include cinnamic aldehyde, cinnamic acid, tannin and methylhydroxychalcone polymer [67]. Recent researches on cinnamon have found that cinnamon extract decreases blood glucose in Wistar rats. Evidence also indicates that cinnamon increases insulin sensitivity and glucose uptake in adipocytes [67]. Studies have suggested that A-type doubly linked procyanidine oligomers of the catechins and/or epicatechins from cinnamon may show insulin-enhancing properties in vitro in adipocytes [68]. One of the probable mechanisms for the hypoglycemic effect of cinnamon is that cinnamon increases glucose entry into cells by enhanced tyrosine phosphorylation of (IR)-β, insulin receptor substrate with Phosphotidylinositol (PI) 3-kinase and GLUT4 translocation to the plasma membrane [69,68]. Syzygium cumuni commonly known as jamun belongs to the family Myrtaceae. Ayurvedic pharmacopedia has acknowledged the anti-diabetic effect of jamun seeds. According to it the seed powder has a significant effect in controlling blood sugar level [70]. Various studies have indicated that several bioactive antioxidant compounds including phenolic acids, flavonoids and anthocyanins are present in a notable amount in the fruits and seeds of jamun which have a role in preventing metabolic syndromes [71]. These bioactive compounds also help in regulating lipid blood profile due to which jamun show antihypercholesterolemic properties [71].

Studies have reported that supplementation of jamun seed powder in human diabetic subjects helps in reducing both fasting and postprandial blood glucose levels. Another study conducted on aqueous extract of jamun seeds showed a significant reduction in blood sugar level, an increase in total hemoglobin and decreased free radical formation [70]. Allium sativum (garlic), a perennial herb cultivated in India and is also one of the major components of Indian spices. Studies have indicated that a sulphur containing amino acid, S-allyl cystine sulphoxide (SACS) which is the precursor of allicin and garlic oil show antidiabetic effects in alloxan diabetic rats. SACS control lipid peroxidation, serum lipids, blood glucose several enzymatic activities and invitro insulin secretion from beta cells isolated from normal rats [65,72]. The hypoglycemic activity of allicin can be explained due to increased hepatic metabolism, increased insulin release from beta cells and/or insulin-sparing effect. The anti-inflammatory, anti-oxidative and anti-glycative effects of garlic may also benefit from the complications and disorders associated with diabetes such as cardiovascular diseases, diabetes nephropathy, activated coagulation, hypertension, dislipidemia and obesity [73]. In addition to herbs normal food including yoghurt were shown to be anti-diabetic. For instance, a study compared the prophylactic activity of conventional yoghurt vs. probiotic yoghurt enriched with bacteria (Lactobacillus acidophilus LA5 and Bifidobacterium animalis-BB12) in a randomized controlled clinical trial involving 70 primigravida-singleton pregnant women revealed that consumption of probiotic yoghurt for 9 weeks daily was much better in preventing the development of insulin resistance in pregnant women than conventional yoghurt [74]. Similarly, another study demonstrated the daily intake of yogurt to reduce the risk of diabetes by 14% on comparison with the group that did not consumed yogurt. Further a review article published earlier analyzed 13 different prospective studies that evaluated the role of yogurt in lowering the risk of diabetes (Table 3). Cumulative analysis of several reviews and research articles clearly states the significance of daily intake of yogurt could be a healthy dietary habit to reduce the TII DM and its associated complications (Figure 3).

Table 3: Herbal plants with anti-diabetic and other beneficial properties. Showing botanical names of plants along with their common names and their anti-diabetic and other beneficial uses.


Figure 3: A summary of influencing factors of diabetes and role of herbal products in prevention of diabetes Lupinepublishers-openaccess-journal-diabetes-obesity indicate inhibition Lupinepublishers-openaccess-journal-diabetes-obesity indicate stimulation.



DM is not only a disease in itself but is also the root cause of other deadly diseases including cancers, heart and kidney related diseases. The disease is ruining the health of almost all ethnicities with the low and middle income groups being its prime targets. Knowing the different context in which DM and its variants could occur and understanding about the underlying causes and their genetic correlation would definitely help in an early diagnosis and subsequent planning of rapid and adequate treatment strategy. Moreover, an early diagnosis would also combat the serious diabetes related complications which are accompanied with diabetes. The economic condition of a common man and the strenuous side effects of some medications have has urged the need for the adoption of effective herbal treatment strategy. The herbal treatment could not only help to combat diabetes and related complication but may also prove to be a complete cure of this pandemic disease.


  1. Cho NH, Show JE, Karuranga S, Huang Y, da Rocha Fernandes JD, et al. (2018) IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projection for 2045. Diabetes Research and Clinical Practice 138: 271-281.
  2. Choby B (2017) Diabetes updates: Prevention and Management of Diabetes Complications. FP Essentials 456: 36-40.
  3. Wu YL, Ding YP, Tanaka Y, Zhang W (2014) Risk Factors Contributing to Type 2 Diabetes and Recent Advances in Treatment and Prevention. International Jounal of Medical Science 11(11): 1185-1200.
  4. Tripathi BK, Srivastava AK (2006) Diabetes mellitus: Complications and Therapeutics. Medical Science Monitor 12(7): 130-147.
  5. Unnikrishnan R, Arjanata RM, Mohan V (2016) Diabetes Mellitus and its complications in India. Nature Reviews Endocrinology 12(6): 357-370.
  6. Murea M, Ma L, Freedman BI (2012) Genetic and Environmental Factors associated with Type 2 Diabetes and Diabetic Vascular Complications. Rev Diabetic Studies 9(1): 6-22.
  7. Lucero P, Chapela S (2018) Euglycemic Diabetic Ketoacidosis in ICU: 3 Case Reports and Review of Literature. Case Reports in Critical Care 2018.
  8. Westerberg DP (2013) Diabetic ketoacidosis: Evaluation and treatment. American Family Physician 87(5): 337-346.
  9. Olokoba AB, Obteru OA, Olokaba LB (2012) Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Medical Journal 27(4): 269-273.
  10. Peterson MC, Shulman GI (2018) Mechanism of insulin action and insulin resistance. Physiological Review 98(4): 2133-2233.
  11. Roith DL, Zick Y (2001) Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 24(3): 588-597.
  12. Whitmarsh AJ (2007) Regulation of gene transcription by mitogen activated protien kinase signaling pathways. Biochimica et Biophysica Acta 1773(8): 1285-1298.
  13. Chiefari E, Arcidiacono B, Foti D, Brunetti A (2017) Gestational Diabetes Mellitus: an updated overview. Journal of Endocrinological Investigation 40(9): 899-909.
  14. Plos JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH (2018) The pathophysiology of gestational diabetes mellitus. International Journal of Molecular Sciences 19(11): 3342.
  15. Horikawa Y (2018) Maturity-onset diabetes of the young as a model for elucidating the multifactorial origin of type 2 diabetes mellitus. Journal of Diabetes Investigation 9(4): 704-712.
  16. Lopez AD, Milliar Garcia A, Segura Kato YX, Riba L, Esparza Lopez R, et al. (2005) Mutation in MODY Genes are not common cause of Early-Onset of Type 2 Diabetes in Mexian families. Journal of Pakistan 6(3): 238-245.
  17. Mohan V, Chari ST, Hitman GA, Suesh S, Madanagopalan NR, et al. (1989) Familial aggregation in Tropical Fibrocalculous Pancreatic Diabetes. Pancrease 4(6): 690-693.
  18. Pearson ER, Boj SF, Steele AM, Barratt T, Stals K, et al. (2007) Macrosomia and hyperinsulinaemic hypoglycemia in patients with heterozygous mutations in the HNF4A gene. PLOS Medicine 4(4): 760-769.
  19. Lebenthal Y, Fisch Shval BN, Gozlan Y, Tenenbaum A, Tenenbaum RY, et al. (2017) The unique clinical spectrum of maturity onset diabetes of the young type3. Diabetes Research and Clinical Practice 135: 18-22.
  20. Rubio Cabezas O, Minton JA, Kantor I, Williams D, Ellard S, Hattersley AT (2010) Homozygous mutations in NEURODI are responsible for a novel syndrome of permanent neonatal diabetes and neurological abnormalities. Diabetes 59(9): 2326-2331.
  21. Unnikrishnan R, Mohan V (2015) Fibrocalculous pancreatic diabetes (FCPD). Acta Diabetologica 52(1): 1-9.
  22. Goudan P, Junqueira A, Kelleher- Yassen D, Steen Kamp D (2016) Fibrocalculous Pancreatic diabetes. Minerva Endocrinologica 41(1): 70-77.
  23. Garg PK, Tandon RK (2004) Survey on chronic pancreatic in the Asia Pacific region. Journal of Gastroenterology and Hepatology 19(9): 998-1004.
  24. Kannan R, Ayyapan SK, Ranga Uand Rajendran K (2013) A Case of Chronic Abdominal Pain. J Clin Diagn Res 7(12): 3121-3122.
  25. Barman KK, Premalatha G, Mohan V (2013) Tropical chronic pancreatitis. Postgraduate Medical Journal 79(937): 606-615.
  26. American Diabetes association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(1): 62-69.
  27. Finsterer J, Frank M (2018) The tip of the iceberg in Maternally Inherited Diabetes & Deafness. Oman Medical Journal 33(5): 437-440.
  28. Yae ML, Wong R, Datta M, Fazio TN, Ebrahim MM, et al. (2018) Mitochondrial disease: an uncommon but important cause of diabetes mellitus. Endocrinology, Diabetes & Metabolism Case Reports.
  29. Murea M, Ma L, Freedman BI (2012) Genetic and Environmental Factors associated with Type 2 Diabetes and Diabetic Vascular Complications. Rev Diabetic Studies 9(1): 6-22.
  30. Steck AK, Rewes MJ (2011) Genetics of Type I Diabetes. Clin Chem 57(2): 176-185.
  31. Bakray M, Pandey R, Hakonanson H (2013) Genes Involved in Type I Diabetes: An update. Genes 4(3): 499-521.
  32. Noble AJ, Valdes AM, Cook M, Klitz W, Thomsom G, Erlich HA (1996) The role of HLA class II genesin insulin dependent diabetes mellitus: Molecular analysis of 180 caucassian multiplex families. American Journal of Human Genetics 59(5): 1134-1148.
  33. Noble AJ, Valdes AM, Bugawan TL, Apple RJ, Thomson G, Erlich HA (2002). The HLA class I A locus affect susceptibility to type I diabetes. Human Immunology 63(8): 657-664.
  34. Valdes AM, Erlich HA, Noble JA (2005) Human leukocyte antigen class 1 B &C loci contribute to type 1 diabetes (T1D) susceptibility and age at T1D onset. Human Immunology 66(3): 301-313.
  35. Tillil H, Kobberling J (1987) Age-corrected empirical genetic risk estimates for first- degree relative of IDDM patients. Diabetes 36(1): 93-99.
  36. Kaprio J, Tumilehh J, Koshenvko M, Romanov K, Reunamen A, et al. (1992) Concordance for type 1(insulin dependent) and type2 (non-insulin dependent) DM in a population-based cohort of twins in Finland. Diabetologica 35(11): 1060-1067.
  37. Bastain W (2002) Genes with linkage or association with type 2 diabetes mellitus. Journal of Pediatric Endocrinology Metabolism 15(1): 471-484.
  38. Rahimi Z, Moradi M, Nasri H (2014) A systematic review of the role of rennin angiotensin aldosterne system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy. Journal of Research in Medical Sciences 19(11): 1090-1098.
  39. Zhou MS, Schulman IH (2009) Prevention of diabetes in hypertensive patients: Results and implications from the VALUE trial. Vascular Health and Risk Managment 5(1): 361-368.
  40. Mueckler M, Thoens B (2013) The SLC2 (GLUT) family of membrane transporters. Molecular Aspects of Medicine 34(2-3): 121-138.
  41. Augustin R (2010) The protein family of glucose transporter facilitators: It’s not only about glucose after all. International Union of Biochemistry and Molecular Biology Life 62(5): 315-333.
  42. Lips P, Eekhoff M, Van School N, Oosterwerff M, De Jongh, et al. (2017) Vitamin D and type 2 diabetes. Journal of Steroid Boiochemistry and Molecular Biology 173: 280-285.
  43. Mirhosseini N, Vatanparast H, Mazidi M, Kimball SM (2018) Vitamin D supplementation, glycemic control, and insulin resistance in prediabetics: A Meta analysis. Journal of Endocrine Society 2(7): 687-709.
  44. Prokopenko J, McCarthy M I, Lindgren CM (2008) Type 2 Diabetes: New genes, new understanding. Trends in Genetics 24(12): 613-621.
  45. Yu F, Cui LL, Li X, Wang CJ, Ba Y, et al. (2016) The genetic polymorphisms in vitamin D receptor and the risk of type 2 diabetes mellitus: an updated meta-analysis. Asian Pacific Journal of Clinical Nutrition 25(3): 614-624.
  46. Harinarayan CV (2014) Vitamin D and diabetes mellitus. Hormones 13(2): 163-181.
  47. He Y, Fan Z, Zhang J, Zheng M, Li Y, et al. (2011) Polymorphism of eNOS gene are associated with diabetic nephropathy: A meta analysis. Metagenesis 26(2): 339-349.
  48. Xu J, Zou MH (2009) Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 120(13): 1266-1286.
  49. Takahashi T, Harris RC (2014) Role of Endothelial Nitric Oxide Synthase in Diabetic Nephropathy: Lessons from diabetic eNOS knockout mice. Journal of Diabetes Research.
  50. Yuen AD, Stead BE, Zhang Y, White KE., Kabir MG, et al. (2012) eNOS deficiency predisposes podocytes to injury in diabetes. Journal of American Society of Nephrology 23(11): 1810-1823.
  51. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH (2018) The pathophysiology of gestational diabetes mellitus. International Journal of Molecular Sciences 19(11): E3342.
  52. Walanabe RM, Black MH, Xiang AH, Allayee H, Lawrence JM, et al. (2007) Genetics of Gestational DM& Type 2 Diabetes. Diabetes Care 30(12): 134-140.
  53. Fajansi SS, Bell GI (2011) MODY History, genetics, pathophysiology and clinical decision making. American Diabetes Association. Diabetes Care 34(8): 1878-1884.
  54. Naylor R, Johanson AK, del Gaudio D (2018) Maturity Onset Diabetes of the Young Overview. Gene Review P: 1-33.
  55. Mohan V, Chari ST, Hitman GA, Suesh S, Madanagopalan NR, et al. (1989) Familial aggregation in Tropical Fibrocalculous Pancreatic Diabetes. Pancrease 4(6): 690-693.
  56. Chowdhury ZM, McDeromott MF, Davey S, Hassan Z, Sinnot PJ, et al. (2002) Genetic susceptibility to Fibrocalculous pancreatic diabetes in Bangladeshi subjects: a family study. Genes & Immunity 3(1): 5-8.
  57. Kombo PK, Hitman GA, Mohan V, Ramachandran A, Snehalatha C, et al. (1989) The genetic predisposition to Fibrocalculous pancreatic diabetes. Diabetologia 32(1): 45-51.
  58. Crispim D, Eslivalet AA, Roisenberg I, Ross JL, Canani LH (2008) Prevalence of 15 mitochondrial DNA mutations among Type 2 Diabetes patients with or without clinical charecteristics of maternally inherited diabetes and deafness. Araquivos Brasileiros Endocrinologia Metabologia 52(8): 1228-1235.
  59. Maissen JA, Janssen GMC, Hart LM (2009) Molecular mechanism of mitochondrial diabetes (MIDD). Annals of Medicine 37(3): 213-221.
  60. Bailey CJ, Day C (1989) Traditional plant medicines as treatment for diabetes. Diabetes Care 12(8): 553-564.
  61. Kooti W, Farokhipour M, Asadzadeh Z, Ashtary Larky D, Samani MA (2016) The role of medicinal plant in the treatment of diabetes: a systematic review. Electronic physician 8(1): 1832-1842.
  62. Dey L, Attele AS, Yuan CS (2002) Alternative therapies of type 2 diabetes. Alternative Medicine Review 7(1): 45-58.
  63. Modak M, Dixit P, Londhe J, Ghaskadbi S, Devasogyam TP (2007) Indian Herbs and Herbal Drugs used for the treatment of diabetes. Journal of Clinical Biochemistry and Nutrition 40(3): 163-173.
  64. Ahn HY, Kim M, Seo CR, Yoo HJ, Lee SH, et al. (2018) The effect of Jerusalem artichoke and fermented soyabean powder mixture supplementation on blood glucose and oxidative stress in subjects with prediabetes or newly diagnosed type 2 diabetes. Nutrition and Diabetes 8(1): 1-42.
  65. Jia W, Gao W, Tang L (2003) Antidiabetic herbal drugs officially approved in China. Phytotherapy Research 17(10): 1127-1134.
  66. Gong J, Fang K, Dong H, Wang D, Hu M, et al. (2016) Efeect of fenugreek on hyperglycemia and hyperglycemia in diabetes and prediabetes: A meta analysis. Journal of Ethnopharmacology 194: 260-268.
  67. Kim SH, Hyun SH, Choung SY (2006) Antidiabetic effect of cinnamon extract on blood glucose in db/db mice. Journal of Ethnopharmacology 104(1-2): 119-123.
  68. Mang B, Wolters M, Schmitt B, Kelb K, Lichtinghagen R, et al. (2006) Effects of a cinnamon extract on plasma glucose, HbA1c serum lipids in DM type 2. European Journal of Clinical Investigation 36(5): 340-344.
  69. Cao H, Polansky MM, Anderson RA (2017) Cinamon extract and polyphenols affect the expression of tris tetraproline, insulin receptor and glucose transporter 4 in mouse 3T3-4 adipocytes. Archives of Biochemistry nad Biophysics 459(2): 214-222.
  70. Prince PS, Menon VP, Pari L (1998) Hypoglycemic activity of Syzigium cumini seeds: effect on lipid peroxidation in alloxan diabetic rats. Journal of Ethnopharmacology 61(1): 1-7.
  71. Gajera HP, Gevariya SN, Hirpara, DG, Patel SV, Golakia BA (2017) Antidiabetic and antioxidant functionality associated with phenolic constituents from fruit parts of indigenous black jamun (Syzygium cumini L.) landraces. Journal of Food Science and Technology 54(10): 3180-3191.
  72. Sheela CG, Augusti KT (1992) Antidiabetic effects of S-allyl cysteine sulphoxide isolated from garlic Allium salivum Linn. Indian Journal of Experimental Biology 30(6): 523-526.
  73. Liu CT, Sheen LY, Lii CK (2007) Does garlic have a role as an antidiabetic agent? Molecular Nutrition and Food Research 51(11): 1353-1364.
  74. Zhang Y, Zhang H (2013) Microbiota associated with type 2 diabetes and its related complications. Food Sciences and Human Wellness 2(3-4): 167-172.
  75. Haghvirdizadeh P, Mohamed Z, Abdullah NA, Hagvirdizadeh P, Haerian MS, et al. (2015) KCNJ11: Genetic Polymorphism and risk of Diabetes Mellitus. Journal of Diabetes Research 2015.
  76. Kim H, Ahn Y (2004) Role of peroxisome proliferator-activated receptor-γ in the glucose sensing apparatus in the liver and β-cell. Diabetes 53(1): 60-65.
  77. Kilpelainen TO, Lakka TA, Laaksonen DE, Lindstrom J, Eriksson JG, et al. (2008) SNPs in PPARG associate with type 2 diabetes and interact with physical activity. Medicine in Science Sports & Exercise 40(1): 25-33.
  78. Babenko AP, Polak M, Cave H, Busain K, Czernichow P, et al. (2006) Activating mutations in ABCC8 Gene in neonatal diabetes mellitus. New England Journal of Medicicne 355(5): 456-466.
  79. Venkatesan R, Bodhini D, Narayani N, Mohan V (2014) Association of ABCC8 gene variants with type 2 diabetes in south Indians. Indian Journal of Human Genetics 20(1): 37-42.
  80. Yousef AA, Behiry EG, Allah WMA, Hussein AM, Abdelmoneam, et al. (2018) IRS-1 genetic polymorphism (r.2963G>A) in type 2 DM patients associated with insulin resistance. Application of Clinical Gentics 11: 99-106.
  81. Arikoglu H, Aksov HM, Erkoc KD, Asik A, Ipekci SH, et al. (2014) IRS1 gene polymorphisms Gly972Arg and Ala513Pro are not associated with insulin resistance and type 2 diabetes risk in non-obese Turkish population. Meta Gene 24(2): 579-585.
  82. Gloyn AL, Braun M, Rorsman P (2009) Type 2 Diabetes Susceptibility Gene TCF7L2 and Its Role in β-Cell Function. Diabetes 58(4): 800-802.
  83. Song Y, NiuT, Manson JE, Kwiatkowski J, Liu S (2004) Are Variants in the CAPN10 Gene Related to Risk of Type 2 Diabetes? A Quantitative Assessment of Population and Family-Based Association Studies. American Journal of Human Genetics 74(2): 208-222.
  84. Mussig K, Staiger H, Machicao F, Kirchhoff K, Guthoff M, et al. (2009) Association of Type 2 Diabetes Candidate Polymorphisms in KCNQ1With Incretin and Insulin Secretion. Diabetes 58(7): 1715-1720.
  85. Rao P, Wang H, Fang H, Gao Q, Zhang J, et al. (2016) Association between IGF2BP2 Polymorphisms and Type 2 Diabetes Mellitus: A Case-Control Study and Meta-Analysis. International Journal of Environmental Research and Public Health 13(6): 574.
  86. Yang Y, Lui B, Xia W, Yan J, Liu HY, et al. (2017) FTO Genotype and Type 2 Diabetes Mellitus: Spatial Analysis and Meta-Analysis of 62 Case-Control Studies from Different Regions. Genes(besel) 8(2): 70.
  87. Lu CC, Chen YT, Chen SY, Hsu YM, Lin CC, et al. (2018) Hematopoietically expressed homeobox gene is associated with type 2 diabetes in KK Cg Ay/J mice and a Taiwanese Han Chinese population. Experiment and Therapeutic Medicine 16(1): 185-191.
  88. Alharabi KK, Khan IA, Syed R, Alharabi FK, Mohammed AK, et al. (2015) Association of JAZF1 and TSPAN8/LGR5 variants in relation to type 2 diabetes mellitus in a Saudi population. Diabetology and Metabolic Syndrome 7: 90-92.
  89. Moradi M, Rahimi Z, Amiri S, Rahimi Z, Vessal M, et al. (2015) AT1R A1166C variants in patients with type 2 diabetes mellitus and diabetic nephropathy. Journal of Nephrology 4(3): 69-76.
  90. Charvet YL, Even P, Faure MB, Millo MG, Moussa NM, et al. (2005) Deletion of angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet induced obeisity and insulin resistance. Diabetes 54(4): 991-999.
  91. Pal A, Potjer PT, Thomsen SK, Ng HJ, Barrett A, et al. (2016) Loss of function mutations in the cell cycle control genes CDKN2A impact on glucose homeosatsis in humans. Diabetes 65(2): 527-533.
  92. Bao XY, Xie C, Yang MS (2012) Association between type 2 diabetes and CDKN2A/B: A meta analysis study. Molecular Biology Reports 39(2): 1609-1616.
  93. Hu C, Jia W (2016) Linking MTNR1B variants to diabetes: the role of circadian rhythms. Diabetes 65(6): 1490-1492.
  94. Safar HA, Chehadeh SHE, Wareth LA, Haq A, Jelinek HF, et al. (2018) Vitamin D receptor gene polymorphisms among Emarti patients with type 2 diabetes mellitus. Journal of Steroid Biochemistry and Molecular Biology 175: 119-124.
  95. Radha V, Kanthimathi S, Anjana RM, Mohan V (2016) Genetics of gestational diabetes mellitus. Diabaetes in Pregenancy Journal of Pakistan Medical Association 66(11): 11-14.
  96. Radha MH, Laxmipriya NP (2015) Evaluation of biological properties and clinical effectiveness of Aloe vera: A systematic review. Journal of traditional and complementary medicine 5(1): 21-26.
  97. Bhatt M, Kothiwale SK, Tirmale AR, Bhargava SY, Joshi BN (2011) Antidiabetic Properties of Azardiracta indica and Bougainvillea spectabilis: In Vivo Studies in Murine Diabetes Model. Evidence-Based Complementary and Alternative Medicine 2011: 1-9.
  98. Singh D, Singh B, Goel RK (2011) Traditional uses, phytochemistry and pharmacology of Ficus religiosa: a review. Journal of Ethnopharmacology 134(3): 565-583.
  99. Jini D, Joseph B (2013) Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian pacific Journal Tropical Disease 3(2): 93-102.
  100. Meliani N, Dib MEA, Tabti B (2011) Hypoglycaemic effect of Berberis vulgaris L. in normal and streptozotocin-induced diabetic rats. Asian pacific Journal Tropical Disease 1(6): 468-471.
  101. Thirumalai T, Therasa SV, Elumalai EK, David E (2011) Hypoglycemic effect of Brassica juncea (seeds) on streptozotocin induced diabetic male albino rate. Asian pacific Journal Tropical Disease 1(4): 323-345.
  102. Parasuraman S, Balamurugan S, Christapher PV, Petchi R, Yeng MW, et al. (2015) Evaluation of Antidiabetic and Antihyperlipidemic Effects of Hydroalcoholic Extract of Leaves of Ocimum tenuiflorum (Lamiaceae) and Prediction of Biological Activity of its Phytoconstituents. Pharmacognosy Research 7(2): 156-165.
  103. Mahendran S, Badami S, Maithili V (2011) Evaluation of antidiabetic effect of embelin from Embelia ribes in alloxan induced diabetes in rats. Biomedicine and preventive nutrition 1(1): 25-31.